PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80009 — DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS

DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS is a federal SBA award for Department of Health and Human Services (HHS) held by CHARTWELL RX LLC. Estimated value $98.7M ($98.7M obligated). Current period of performance ends Jun 22, 2029. Last award drew 2 bidders. Place of performance: CONGERS, NY.

$98.7M
Estimated Value
Jun 22, 2029
PoP End / Expires
2
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

CHARTWELL RX LLC holds $76.0M across 516 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 2 offers. Set-aside status: SBA. Recompete timing centers on the Jun 22, 2029 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

SBA
Contract number75A50325F80009
AgencyDepartment of Health and Human Services (HHS)
IncumbentCHARTWELL RX LLC
UEIER5UA9TYBGH4
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79720D0198
Place of performanceCONGERS, NY
PoP end (current)Jun 22, 2029
Obligated$98.7M

Recompete timing

Public
Expiring in 1040 days

Current PoP ends Jun 22, 2029 (1040 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Dec 22, 2027.

Watch this contract — one email →

Incumbent footprint

Public record

CHARTWELL RX LLC$76.0M obligated across 516 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($76.0M) · all agencies
Department of Health and Human Services (HHS)$74.1M · 98%Department of Defense (DOD)$1.9M · 3%
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open CHARTWELL RX LLC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50325F80009?

75A50325F80009 (DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS) is a Department of Health and Human Services (HHS) award with an estimated value of $98.7M, currently held by CHARTWELL RX LLC. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50325F80009?

CHARTWELL RX LLC is the incumbent with $76.0M across 516 related awards in SCOUT’s public footprint. The current period of performance ends Jun 22, 2029.

When does 75A50325F80009 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 22, 2029. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36F79720D0198-75A50325F80009